UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015120
Receipt number R000017591
Scientific Title Pilot study of efficacy and safety of Rikkunshito for adverse events (nausea, emesis and anorexia) caused by chemotherapy (GD therapy) for high-grade soft tissue sarcomas.
Date of disclosure of the study information 2014/10/01
Last modified on 2014/09/11 14:25:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Pilot study of efficacy and safety of Rikkunshito for adverse events (nausea, emesis and anorexia) caused by chemotherapy (GD therapy) for high-grade soft tissue sarcomas.

Acronym

Pilot study of Rikkunshito for adverse events caused by chemotherapy (GD therapy).

Scientific Title

Pilot study of efficacy and safety of Rikkunshito for adverse events (nausea, emesis and anorexia) caused by chemotherapy (GD therapy) for high-grade soft tissue sarcomas.

Scientific Title:Acronym

Pilot study of Rikkunshito for adverse events caused by chemotherapy (GD therapy).

Region

Japan


Condition

Condition

High-grade soft tissue sarcomas

Classification by specialty

Orthopedics

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of Rikkunshito on nausea, emesis and anorexia caused by anti-cancer drug

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Nausea, emesis and anorexia (CTCAE ver4.0), EORTC QLQ-C30(version3)

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Rikkunnshito
7.5g/day, 14days

Interventions/Control_2

No Rikkunnshito

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

15 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with histologically-proved high-grade bone and soft tissue sarcoma

Patients firstly applied modified MAID regimen

Patients with healthy vital organs
WBC >3000/mm3 and <20000/mm3
Neutrophils >1500/mm3
Hb >8.0g/dl
Plat >8X104/mm3
Total Bil <2.0mg/dl
ALT/AST <150IU/l
Cr <1.5mg/dl

Performance Status (ECOG) 0-2

Key exclusion criteria

1. Patients with double cancer
2. Patients who took Kampo within 4 weeks
3. Patients with any other severe diseases
4. Pregnat patients
5. Other exclusionary comobidity

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takahiro Goto

Organization

Tokyo Metropolitan Komagome Hospital

Division name

Department of Musculoskeletal Oncology

Zip code


Address

3-18-22, Hon-Komagome, Bunkyo-ku, Tokyo

TEL

03-3823-2101

Email

goto-tky@cick.jp


Public contact

Name of contact person

1st name
Middle name
Last name Takahiro Goto

Organization

Tokyo Metropolitan Komagome Hospital

Division name

Department of Musculoskeletal Oncology

Zip code


Address

3-18-22, Hon-Komagome, Bunkyo-ku, Tokyo

TEL

03-3823-2101

Homepage URL


Email

goto-tky@cick.jp


Sponsor or person

Institute

Tokyo Metropolitan Komagome Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2014 Year 06 Month 30 Day

Date of IRB


Anticipated trial start date

2014 Year 10 Month 06 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 09 Month 11 Day

Last modified on

2014 Year 09 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017591


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name